慢性乙型肝炎与调节性T细胞研究进展*

doi:10.3969/j.issn.1672-5069.2019.05.002

实用肝脏病杂志 ›› 2019, Vol. 22 ›› Issue (5): 613-616.doi: 10.3969/j.issn.1672-5069.2019.05.002

慢性乙型肝炎与调节性T细胞研究进展^*

杜科业, 杨东亮, 刘嘉

430032 武汉市华中科技大学同济医学院附属协和医院感染病科

收稿日期:2019-07-02 出版日期:2019-09-10 发布日期:2019-09-16
通讯作者: 杨东亮,E-mail: dlyang@hust.edu.cn
基金资助:
国家自然科学基金资助项目（编号：81861138044/91642118/91742114）; 国家科技重大专项资助项目（编号：2017ZX10202202/2017ZX10202201/ 2017ZX10202203-007-006）; 华中科技大学同济医学院重大疾病交叉创新团队资助项目（编号：0027）

Regulatory T cells in hepatitis B

Du Keye, Yang Dongliang, Liu Jia

Department of Infectious Diseases,Union Hospital,Affiliated to Tongji Medical School,Huazhong University of Science and Technology,Wuhan 430032, Hubei Province,China

Received:2019-07-02 Online:2019-09-10 Published:2019-09-16

摘要/Abstract

关键词: 乙型肝炎, 调节性T细胞, 研究进展

Key words: Hepatitis B, Regulatory T cells, Progress

杜科业, 杨东亮, 刘嘉. 慢性乙型肝炎与调节性T细胞研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 613-616.

Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B[J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.

[1] Alter MJ,Mast EE.The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am,1994,23:437-455.
[2] Thimme R,Wieland S,Steiger C,et al.CD8(+)T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol,2003,77:68-76.
[3] Rehermann B,Nascimbeni M.Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol,2005,5:215-229.
[4] Alroqi FJ,Chatila TA.T regulatory cell biology in health and disease. Curr Allergy Asthma Rep,2016,16:27.
[5] Gershon RK.A disquisition on suppressor T cells. Transplant Rev,1975,26:170-185.
[6] Sakaguchi S,Fukuma K,Kuribayashi K,et al.Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance;deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med,1985,161:72-87.
[7] Sakaguchi S,Sakaguchi N,Asano M,et al.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains(CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol,1995,155:1151-1164.
[8] Baecher-Allan C,Viglietta V,Hafler DA.Human CD4⁺CD25⁺ regulatory T cells. Semin Immunol,2004,16:89-98.
[9] Hori S,Nomura T,Sakaguchi S.Control of regulatory T cell development by the transcription factor Foxp3. Science,2003,299:1057-1061.
[10] Bettelli E,Carrier Y,Gao W,et al.Reciprocal developmentalpathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature,2006,441:235-238.
[11] Mills KH. Regulatory T cells:friend or foe in immunity to infection Nat Rev Immunol,2004,4:841-855.
[12] Sakaguchi S.Naturally arising Foxp3-expressing CD25⁺CD4⁺ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol,2005,6:345-352.
[13] Jordan MS,Boesteanu A,Reed AJ,et al.Thymic selection of CD4⁺CD25⁺ regulatory T cells induced by an agonist self-peptide. Nat Immunol,2001,2:301-306.
[14] Andre S,Tough DF,Lacroix-Desmazes S,et al.Surveillance of antigen-presenting cells by CD4⁺CD25⁺ regulatory T cells in autoimmunity:immunopathogenesis and therapeutic implications. Am J Pathol,2009,174:1575-1587.
[15] Walker MR,Kasprowicz DJ,Gersuk VH,et al.Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4⁺CD25^-T cells. J Clin Invest,2003,112:1437-1443.
[16] Groux H,Fournier N,Cottrez F.Role of dendritic cells in the generation of regulatory T cells. Semin Immunol,2004,16:99-106.
[17] Lu Y,Wang X,Gu J,et al.iTreg induced from CD39(+) naive T cells demonstrate enhanced proliferate and suppressive ability. Int Immunopharmacol,2015,28:925-930.
[18] Trehanpati N,Shrivastav S,Shivakumar B,et al.Analysis of notch and TGF-beta signaling expression in different stages of disease progression during hepatitis B virus infection. Clin Transl Gastroenterol,2012,3:e23.
[19] Asano N,Watanabe T,Kitani A,et al.Notch1 signaling and regulatory T cell function. J Immunol,2008,180:2796-2804.
[20] Moore KW,de Waal Malefyt R,Coffman RL,et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol,2001,19:683-765.
[21] Read S,Malmstrom V,Powrie F.Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med,2000,192:295-302.
[22] de la Rosa M,Rutz S,Dorninger H,et al. Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur J Immunol,2004,34:2480-2488.
[23] Tran DQ,Glass DD,Uzel G,et al.Analysis of adhesion molecu-les,target cells,and role of IL-2 in human FOXP3+ regulatory T cell suppressor function. IL-2 in human FOXP3+ regulatory T cell suppressor function. J Immunol,2009,182:2929-2938.
[24] Collison LW,Workman CJ,Kuo TT,et al.The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature,2007,450:566-569.
[25] Collison LW,Chaturvedi V,Henderson AL,et al.IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol,2010,11:1093-1101.
[26] Chaturvedi V,Collison LW,Guy CS,et al.Cutting edge:Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol,2011,186:6661-6666.
[27] Dietze KK,Schimmer S,Kretzmer F,et al.Characterization of the Treg response in the hepatitis B virus hydrodynamic injection mouse model. PloS one,2016,11:e0151717.
[28] Stross L,Gunther J,Gasteiger G,et al.Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice. Hepatology,2012,56:873-883.
[29] Xu D,Fu J,Jin L,et al.Circulating and liver resident CD4⁺CD25⁺ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol,2006,177:739-747.
[30] Yan Z,Zhou J,Zhang M,et al.Telbivudine decreases proportion of peripheral blood CD4⁺CD25⁺CD127low T cells in parallel with inhibiting hepatitis B virus DNA. Mol Med Rep,2014,9:2024-2030.
[31] Stoop JN,van der Molen RG,Kuipers EJ,et al. Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. Virology,2007,361:141-148.
[32] Feng H,Yin J,Han YP,et al.Sustained changes of Treg and Th17 cells during interferon-alpha therapy in patients with chronic hepatitis B. Viral Immunol,2015,28:412-417.
[33] Yang X,Li J,Liu J,et al.Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment:A longitudinal observational study. Medicine (Baltimore),2017,96:e7064.
[34] Das A,Ellis G,Pallant C,et al.IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol,2012,189:3925-3935.
[35] Xiang XG,Xie Q.IL-35:a potential therapeutic target for controlling hepatitis B virus infection. J Dig Dis,2015,16:1-6.
[36] Wang X,Dong Q,Li Q,et al.Dysregulated response of follicular helper T cells to hepatitis B surface antigen promotes HBV persistence in mice and associates with outcomes of patients. Gastroenterology,2018,154:2222-2236.

慢性乙型肝炎与调节性T细胞研究进展^*

Regulatory T cells in hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[6]	马丽英, 沈利娟. 妊娠后期应用替诺福韦治疗血清HBV高载量孕妇阻断HBV母婴传播的疗效及安全性分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 836-839.
[7]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[8]	廖桂婵, 彭颉, 张小勇. 肝细胞介导的天然免疫应答参与控制乙型肝炎病毒感染^*[J]. 实用肝脏病杂志, 2019, 22(5): 617-619.
[9]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[10]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[11]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[12]	朱玉成, 闫家微, 孙景坤, 张秋月. 慢加急性肝衰竭患者血清二胺氧化酶水平及其临床意义探讨*[J]. 实用肝脏病杂志, 2019, 22(5): 672-675.
[13]	张梅, 石秀英, 李林娟, 薛亚妮. 肝源性糖尿病患者肝组织干扰素诱导蛋白-10表达变化*[J]. 实用肝脏病杂志, 2019, 22(5): 688-691.
[14]	陈嵘, 黄美玲, 凌雪梅, 林小红, 曾俊, 黎云, 夏建红. 替比夫定联合HBIG和乙肝疫苗阻断HBV母婴传播临床效果分析*[J]. 实用肝脏病杂志, 2019, 22(5): 752-753.
[15]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.